N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness

J Jeremy M. Robbins M Mark Benson (Division of Cardiovascular Medicine (J.M.R., M.B., P.R., U.A.T., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.) A Anthony R.P. Verkerke (Division of Endocrinology, Diabetes and Metabolism (A.R.P.V., S.K.), Beth Israel Deaconess Medical Center, Boston, MA.) G Gaurav Tiwari S Shuliang Deng (Cardiovascular Research Center (J.M.R., M.B., G.T., S.D., P.R., U.A.T., X.S., Y.G., F.-G.T., J.L.B., J.G.W., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.t) P Prashant Rao (Beth Israel Deaconess Medical Ctr, Boston, Massachusetts, United States) U Usman A. Tahir J Julian Avila-Pacheco (Broad Institute of Massachusetts Institute of Technology and Harvard) X Xu Shi Y Yuntian Guan F Foje-Geh Tendoh (Cardiovascular Research Center (J.M.R., M.B., G.T., S.D., P.R., U.A.T., X.S., Y.G., F.-G.T., J.L.B., J.G.W., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.t) J Jacob L. Barber (Cardiovascular Research Center (J.M.R., M.B., G.T., S.D., P.R., U.A.T., X.S., Y.G., F.-G.T., J.L.B., J.G.W., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.t) P Patricia E. Miller (Department of Biostatistics, Boston University School of Public Health, MA (P.E.M.).) A Andrew S. Perry M Michael E. Hall (Department of Medicine, University of Mississippi Medical Center, Jackson, MS (M.E.H.).) A Alexis C. Wood K Kent D. Taylor (The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.) W Wendy S. Post S Stephen S. Rich (Department of Genome Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA.) M Matthew Nayor J James G. Wilson G Gregory D. Lewis (Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston) R Ravi V. Shah J Jerome I. Rotter S Scott A. Summers L Laura M. Raffield (Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.) S Shingo Kajimura C Claude Bouchard (PENNINGTON BIOMEDICAL RESEARCH CTR, Baton Rouge, Louisiana, United States) C Clary B. Clish (Broad Institute of Massachusetts Institute of Technology and Harvard) M Mark A. Sarzynski (Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia (M.A.S.).) R Robert E. Gerszten

Abstract

BACKGROUND: Cardiorespiratory fitness is an integrative measure of cardiometabolic health and predictor of survival, yet little is known about its molecular underpinnings. Small molecule metabolites and lipids are increasingly recognized as exercise-stimulated signaling molecules and candidate molecular transducers of cardiorespiratory fitness. METHODS: We performed nontargeted liquid chromatography mass spectrometry–based plasma metabolomics in 654 participants (mean age, 35 years; 55% women) from the HERITAGE Family Study (Health, Risk Factors, Exercise Training, and Genetics) who had cardiorespiratory fitness (maximal oxygen uptake [VO 2 max]) measured by cardiopulmonary exercise testing and underwent 20 weeks of supervised endurance training. Metabolite–VO 2 max relationships were assessed using linear regression and tested for replication in FHS (Framingham Heart Study) participants who also underwent cardiopulmonary exercise testing. Metabolite relationships with incident all-cause mortality ascertained in JHS (Jackson Heart Study) and MESA (Multi-Ethnic Study of Atherosclerosis) were tested using Cox regression. Experimental studies of cellular respiration and mitochondrial function were performed in C2C12 myotubes. RESULTS: An unknown mass spectrometry peak (mass-to-charge, 385.3056; retention time, 3.69 minutes) had the strongest, positive relationship with VO 2 max (mL×kg −1 min −1 ) after adjustment for age, sex, race, and lean body mass (β=1.29; false discovery rate q =5.3×10 −6 ); was identified as N-palmitoyl glutamine (N-pal-gln) using tandem mass spectrometry and bioinformatics; and was confirmed with an authentic chemical standard. The biological role of N-pal-gln has not been described previously. The relationship of N-pal-gln with VO 2 max was validated in 408 participants from the FHS (β=1.2; P =3.8×10 −5 ), and its levels increased after exercise training (log fold change=0.22; q =5.3×10 −12 ). N-pal-gln levels were inversely associated with all-cause mortality in JHS and MESA (hazard ratio, 0.91 and 0.65 [ P =0.029 and P =0.028], respectively). Previous studies have shown that structurally related biochemicals modulate energy homeostasis; thus, we performed mitochondrial experiments. N-pal-gln administration led to a dose-dependent increase in mitochondrial:nuclear DNA ratio compared with control treated cells (15% and 20% increases at 6.5 nM and 26 nM N-pal-gln, respectively [ P =0.04 and P =0.02]) and improved bioenergetics (N-pal-gln at 26 nM increased the phosphate:oxygen ratio across ADP concentrations from 0 to 100 μM; ANOVA P =0.0027). CONCLUSIONS: We identified a novel, lipidated amino acid, N-pal-gln, that is positively associated with VO 2 max, increases after regular aerobic exercise, and is inversely associated with incident mortality. N-pal-gln stimulates mitochondrial biogenesis and efficiency, demonstrating its potential role as an exercise-stimulated transducer of cardiorespiratory fitness.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue 1
Published January 06, 2026
Pages 47-58
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (31)

J

Jeremy M. Robbins

M

Mark Benson

Division of Cardiovascular Medicine (J.M.R., M.B., P.R., U.A.T., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.

A

Anthony R.P. Verkerke

Division of Endocrinology, Diabetes and Metabolism (A.R.P.V., S.K.), Beth Israel Deaconess Medical Center, Boston, MA.

G

Gaurav Tiwari

S

Shuliang Deng

Cardiovascular Research Center (J.M.R., M.B., G.T., S.D., P.R., U.A.T., X.S., Y.G., F.-G.T., J.L.B., J.G.W., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.t

P

Prashant Rao

Beth Israel Deaconess Medical Ctr, Boston, Massachusetts, United States

U

Usman A. Tahir

J

Julian Avila-Pacheco

Broad Institute of Massachusetts Institute of Technology and Harvard

X

Xu Shi

Y

Yuntian Guan

F

Foje-Geh Tendoh

Cardiovascular Research Center (J.M.R., M.B., G.T., S.D., P.R., U.A.T., X.S., Y.G., F.-G.T., J.L.B., J.G.W., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.t

J

Jacob L. Barber

Cardiovascular Research Center (J.M.R., M.B., G.T., S.D., P.R., U.A.T., X.S., Y.G., F.-G.T., J.L.B., J.G.W., R.E.G.), Beth Israel Deaconess Medical Center, Boston, MA.t

P

Patricia E. Miller

Department of Biostatistics, Boston University School of Public Health, MA (P.E.M.).

A

Andrew S. Perry

M

Michael E. Hall

Department of Medicine, University of Mississippi Medical Center, Jackson, MS (M.E.H.).

A

Alexis C. Wood

K

Kent D. Taylor

The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.

W

Wendy S. Post

S

Stephen S. Rich

Department of Genome Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA.

M

Matthew Nayor

J

James G. Wilson

G

Gregory D. Lewis

Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston

R

Ravi V. Shah

J

Jerome I. Rotter

S

Scott A. Summers

L

Laura M. Raffield

Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

S

Shingo Kajimura

C

Claude Bouchard

PENNINGTON BIOMEDICAL RESEARCH CTR, Baton Rouge, Louisiana, United States

C

Clary B. Clish

Broad Institute of Massachusetts Institute of Technology and Harvard

M

Mark A. Sarzynski

Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia (M.A.S.).

R

Robert E. Gerszten